CHO cell clinical trials
How each study uses CHO cell is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CHO cell studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
35 studies that test it; most in 2021 (11)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 11 |
| 2022 | 7 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 30 · Other 5
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (12) · MAXVAX Biotechnology Limited Liability Company (5) · Jiangsu Rec-Biotechnology Co., Ltd. (5) · Ab&B Bio-tech Co., Ltd.JS (2) · National Vaccine and Serum Institute, China (2) · Guangzhou Patronus Biotech Co., Ltd. (2) · Jiangsu Province Centers for Disease Control and Prevention (2) · Shenyang Sunshine Pharmaceutical Co., LTD. (2)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test CHO cell.
- Nov 2026Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and OlderPhase 1/2 · Ab&B Bio-tech Co., Ltd.JS
- Jan 2027Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and OlderPhase 1 · Yikang Biotech (Suzhou) Co., Ltd.
- Jul 2027Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and AbovePhase 1/2 · CSPC Megalith Biopharmaceutical Co.,Ltd.
- Sep 2027Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older.Phase 1/2 · Ab&B Bio-tech Co., Ltd.JS
Studies
Open first, then newest update. How each study uses CHO cell is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 35
- Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and AboveNot yet recruitingPhase 1/2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07892989Written as Recombinant Zoster Vaccine (CHO cell) SYS6052
- Phase III Clinical Trial of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)RecruitingPhase 3Beijing BeneWill Technology Development Co., LtdNCT07860216Written as Recombinant respiratory syncytial virus vaccine (CHO cell)
- Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and OlderNot yet recruitingPhase 1Yikang Biotech (Suzhou) Co., Ltd.NCT07807449Written as Recombinant RSV Vaccine (CHO Cell)
- A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)Not yet recruitingNot applicableMAXVAX Biotechnology Limited Liability CompanyNCT07618325Written as Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)
- Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older.RecruitingPhase 1/2Ab&B Bio-tech Co., Ltd.JSNCT07582796Written as Recombinant Respiratory Syncytial Virus Vaccine(CHO cell)(Adjuvanted)
- Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)RecruitingPhase 3MAXVAX Biotechnology Limited Liability CompanyNCT07272434Written as Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)
- Safety Study of COVID19 Vaccine on the MarketRecruitingPhase 4Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.NCT05890521Written as Recombinant new coronavirus vaccine (CHO cell)
- Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and OlderActive, not recruitingPhase 1/2Ab&B Bio-tech Co., Ltd.JSNCT06851832Written as Recombinant zoster vaccine(CHO cell)(low adjuvant)
- Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and OlderActive, not recruitingPhase 3MAXVAX Biotechnology Limited Liability CompanyNCT06447779Written as Recombinant Zoster Vaccine (CHO Cell)
- A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)Active, not recruitingPhase 3MAXVAX Biotechnology Limited Liability CompanyNCT07293065Written as Recombinant Zoster Vaccine (CHO Cell)
- Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).CompletedPhase 3MAXVAX Biotechnology Limited Liability CompanyNCT06654700Written as Recombinant Zoster Vaccine (CHO Cell)
- A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19CompletedPhase 1/2National Vaccine and Serum Institute, ChinaNCT04869592Written as low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
- Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)CompletedNot applicableAnhui Zhifei Longcom Biologic Pharmacy Co., Ltd.NCT05574985Written as Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)
- The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)CompletedPhase 1Jiangsu Rec-Biotechnology Co., Ltd.NCT05769049Written as REC610
- Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)CompletedPhase 2Jiangsu Rec-Biotechnology Co., Ltd.NCT05084989Written as Part1:Recombinant two-component COVID-19 vaccine (CHO cell)
- Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)CompletedPhase 3Jiangsu Rec-Biotechnology Co., Ltd.NCT05398848Written as Recombinant two-component COVID-19 vaccine (CHO cell)
- Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or OlderTerminatedPhase 3Guangzhou Patronus Biotech Co., Ltd.NCT05683600Written as Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001
- Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and AboveStatus unknownPhase 3Guangzhou Patronus Biotech Co., Ltd.NCT05664932Written as Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001
- Clinical Study of Recombinant Novel Coronavirus(COVID-19) Vaccine (CHO Cell) Combined With Influenza VaccineCompletedPhase 3Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.NCT05107375Written as Recombinant new coronavirus vaccine (CHO cell) group
- Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)CompletedPhase 2Jiangsu Rec-Biotechnology Co., Ltd.NCT05323435Written as Recombinant two-component COVID-19 vaccine (CHO cell)
See all 35 studies that test CHO cell →
Given beside what is tested · 1 — CHO cell is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with CHO cell
- Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102)CompletedPhase 1WestVac Biopharma Co., Ltd.NCT05765604Written as Recombinant COVID-19 vaccine(CHO cell)
- Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)CompletedPhase 2WestVac Biopharma Co., Ltd.NCT05770180Written as Recombinant COVID-19 vaccine (CHO cell)
What changed recently
From the registry's own updates since Oct 17, 2026.
Newly registered1
- Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and AboveOct 23, 2026NCT07892989